Side-effects of long-term immunosuppression versus morbidity in autologous stem cell rescue: Striking the balance

Rheumatology

Volumn 38, Issue 8, 1999, Pages 747-750

  Niethammer, D ^a   Kummerle Deschner J ^a   Dannecker, G E ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEUKOTRIENE; METHOTREXATE; PROSTAGLANDIN; STEROID;

AUTOIMMUNE DISEASE; AUTOTRANSPLANTATION; CANCER; CONFERENCE PAPER; DNA SYNTHESIS; GROWTH DISORDER; HUMAN; INFECTION; LYMPHOMA; MORBIDITY; OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL TRANSPLANTATION;

ARTHRITIS, JUVENILE RHEUMATOID; AUTOIMMUNE DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; METHOTREXATE; MORBIDITY; TIME; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032732944     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.8.747     Document Type: Conference Paper

References (28)

1. Marmont AM. Stem cell transplantation for severe autoimmune disorders, with special reference to rheumatic diseases. J Rheumatol 1997;48(suppl.):13-8.
2. Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol 1997;99:9-22.
3. Snowden JA, Patton WN, O'Donnell JL, Hannah EE, Hart DN. Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 1997;19:1247-50.
4. Tyndall A et al. Treatment of systemic sclerosis with autologous haematopoietic stem cell transplantation. Lancet 1997;349:254.
5. Tyndall A, Gratwohl A. Hemopoietic blood and marrow transplants in the treatment of severe autoimmune disease. Curr Opin Hematol 1997;4:390-4.
6. Tyndall A, Gratwohl A. Bone marrow transplantation in the treatment of autoimmune diseases. Br J Rheumatol 1997;36:1-3.
7. von Boehmer H. Positive and negative selection of the T-cell repertoire in vivo. Curr Opin Immunol 1991;3:210-5.
8. Farrell HE, Vally H, Lynch DM, Fleming P, Shellam GR, Scalzo AA et al. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 1997;386:510-4.
9. Hengel H, Koszinowski UH. Interference with antigen processing by viruses. Curr Opin Immunol 1997;9:470-6.
10. Reyburn HT, Mandelboim O, Vales Gomez M, Davis DM, Pazmany L, Strominger JL. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997;386:514-7.
11. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998; 41:761-7.
12. Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 1994;20:513-28.
13. Grosflam J, Weinblatt ME. Methotrexate: mechanism of action, pharmacokinetics, clinical indications, and toxicity. Curr Opin Rheumatol 1991;3:363-8.
14. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13:136-42.
15. Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995;24:411-21.
16. Kanik KS, Cash JM. Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin North Am 1997;23:955-67.
17. Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997;26:794-804.
18. Padeh S, Sharon N, Schiby G, Rechavi G, Passwell JH. Hodgkin's lymphoma in systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol 1997;24:2035-7.
19. Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995;38:1120-7.
20. Giannini EH, Cawkwell GD. Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. Pediatr Clin North Am 1995;42:1099-125.
21. Moreland LW, Heck LW, Koopman WJ. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum 1997;40:397-409.
22. Moreland LW, Heck LW Jr, Koopman WJ, Saway PA, Adamson TC, Fronek Z et al. V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study. J Rheumatol 1996;23: 1353-62.
23. Horneff G, Dirksen U, Schulze Koops H, Emmrich F, Wahn V. Treatment of refractory juvenile chronic arthritis by monoclonal CD4 antibodies: a pilot study in two children. Ann Rheum Dis 1995;54:846-9.
24. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994;37:992-9.
25. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, IL-1Ra Arthritis Study Group. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
26. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
27. Garrison L, Lovell DJ, Giannini EH, Whitmore JB, Soffes L, Finck BK. Safety and efficacy of a tumor necrosis factor receptor p75 Fc fusion protein (TNFR:FC; EnbrelTM) in polyarticular course juvenile rheumatoid arthritis. Presented at the American College of Rheumatology, 62nd National Meeting, November 8-12, 1998, San Diego, CA.
28. Elliott MJ, Maini RN, Feldman M, Kalden JR, Antoni C, Smolen JS et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.